Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR0302 tablets in adults with moderate to severe atopic dermatitis
CTR20190969Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in atopic dermatitis (AD), sponsored by Reistone Biopharma. Started Jul 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20190969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190969.